Wealthcare Advisory Partners’s ARK Genomic Revolution ETF ARKG Stock Holding History

Wealthcare Advisory Partners’s Portfolio ARKG Stock Details ARKG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.09M	Buy	25,946 +8,808	+51%	+$280K	0.02%	496
2026 Q1	$453K	Sell	17,138 -2,669	-13%	-$78.2K	0.01%	729
2025 Q4	$574K	Buy	19,807 +3,480	+21%	+$104K	0.01%	652
2025 Q3	$453K	Buy	16,327 +649	+4%	+$16.4K	0.01%	708
2025 Q2	$382K	Buy	15,678 +590	+4%	+$12.9K	0.01%	718
2025 Q1	$313K	Sell	15,088 -815	-5%	-$20.5K	0.01%	730
2024 Q4	$374K	Buy	15,903 +435	+3%	+$10.7K	0.01%	648
2024 Q3	$396K	Sell	15,468 -1,815	-11%	-$46.2K	0.01%	630
2024 Q2	$406K	Buy	+17,283	New	+$436K	0.01%	582
2022 Q2	–	Sell	-5,029	Closed	-$231K	–	566
2022 Q1	$231K	Sell	5,029 -1,005	-17%	-$47.9K	0.01%	484
2021 Q4	$370K	Sell	6,034 -336	-5%	-$23.2K	0.02%	389
2021 Q3	$476K	Sell	6,370 -1,306	-17%	-$110K	0.03%	327
2021 Q2	$710K	Sell	7,676 -1,313	-15%	-$112K	0.05%	246
2021 Q1	$798K	Buy	8,989 +2,560	+40%	+$254K	0.06%	221
2020 Q4	$600K	Buy	+6,429	New	+$512K	0.05%	209
2020 Q2	–	Sell	-759	Closed	-$24K	–	378
2020 Q1	$24K	Buy	+759	New	+$25.4K	﹤0.01%	683

Other funds holding ARKG

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

State of Wisconsin Investment Board Madison, Wisconsin $49.6B AUM 39.59% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Wealthcare Advisory Partners's ARKG Position: Q2 2026 in Review

Wealthcare Advisory Partners increased its ARK Genomic Revolution ETF (ARKG) stake by 51% in Q2 2026, buying an estimated $280K and bringing the position to 25,946 shares worth $1.09M. The position accounts for 0.02% of the portfolio, ranked #496.

Wealthcare Advisory Partners first reported a position in ARKG in Q1 2020 and has held it in 16 quarters since. 272 funds tracked by Wall St. Rank hold ARKG as of Q2 2026.

Wealthcare Advisory Partners held 25,946 shares of ARK Genomic Revolution ETF worth $1.09M as of Q2 2026.
Wealthcare Advisory Partners bought 8,808 ARK Genomic Revolution ETF shares in Q2 2026, an estimated $280K.
ARK Genomic Revolution ETF made up 0.02% of Wealthcare Advisory Partners's portfolio in Q2 2026, its #496 holding.
Wealthcare Advisory Partners first reported a position in ARK Genomic Revolution ETF in Q1 2020 and has held it in 16 quarters since.
272 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q2 2026.

Based on Wealthcare Advisory Partners's 13F filing for Q2 2026, filed 9 Jul 2026.